ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.19% | -75.96% | 211.61% | 12.00% | 80.06% |
| Total Depreciation and Amortization | 4.52% | 1.29% | 0.21% | -5.23% | -3.17% |
| Total Amortization of Deferred Charges | -15.79% | -13.24% | -13.10% | 11.01% | -10.28% |
| Total Other Non-Cash Items | -3.82% | 110.33% | -2,561.63% | 11.38% | 32.94% |
| Change in Net Operating Assets | 59.47% | -513.55% | 184.58% | -291.30% | 134.59% |
| Cash from Operations | 207.44% | -139.18% | 100.64% | -45.17% | 2,157.98% |
| Capital Expenditure | 48.48% | -70.51% | -161.08% | 48.89% | 11.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -452.63% | -371.43% | 116.67% | 85.95% | -1,893.33% |
| Cash from Investing | 46.46% | -71.64% | -150.46% | 53.57% | -0.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00% | -- | -- |
| Issuance of Common Stock | 1,943.56% | -77.20% | -92.22% | 1,619.34% | -67.83% |
| Repurchase of Common Stock | 83.52% | -1,022.36% | 44.39% | -67.10% | 72.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.67% | 77.03% | -21.83% | -6,935.08% | 74.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 159.20% | -291.74% | 1,169.62% | -103.58% | 812.11% |